News | September 10, 2007

Simple Blood Test Detects Breast Cancer Early

September 11, 2007 —The BC-SeraPro blood serum test for detection of breast cancer is being developed by Power3, in conjunction with Mercy Hospital Women's Center.

The test analyzes biomarkers, or specific proteins, that indicate the difference between normal breast tissue, a benign breast disease, and a breast cancer. A recent study showed that the BC-SeraPro diagnostic test detected the disease accurately in 80 to 90 percent of the patients.

Proteomics, the state-of-the-art technology that Power3 applies, involves identifying protein biomarkers that differ from the body's normal protein markers. These particular markers can be used to both detect diseases early and as targets for new drug treatments. Using proteomics, distinctive proteins can be mapped to create a profile of a disease that is distinctive for that particular disease. Power3 has identified 22 biomarkers that are utilized in the detection of early breast cancer.

In addition to its usefulness in offering early diagnosis, BC-SeraPro can potentially monitor the progression of the disease to determine if a specific therapy is effective.

For more information:

Related Content

FDA Approves Exablate Neuro for Tremor-Dominant Parkinson's Treatment
Technology | Focused Ultrasound Therapy | December 21, 2018
Insightec announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication of...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
News | Radiation Dose Management | September 24, 2018
AngioDynamics Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
MR-HIFU, ThermoDox, combination therapy, recurrent childhood tumors, Celsion, Children's National Health System, Phase I clinical study
News | Oncology Related Products | December 19, 2016
December 19, 2016 — Children’s National Health System and Celsion Corp.
News | Clinical Decision Support | October 27, 2016
October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use
contrast-enhanced ultrasound, CEUS, liver cancer, hepatocellular carcinoma, study, Advances in Contrast Ultrasound conference, ICUS
News | Ultrasound Imaging | September 12, 2016
September 12, 2016 — Tiny microbubbles are being used to more effectively...
cardio-oncology, echo strain assessment, echoinsight, epsilon

Epsilon's EchoInsight software helps analyze cardiac function by evaluating wall motion strain. 

Feature | Cardio-oncology | May 13, 2016 | Dave Fornell
Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat
Carestream, Clinical Collaboration Platform, Fox Valley Hematology & Oncology
News | Enterprise Imaging | April 20, 2016
Fox Valley Hematology & Oncology (Appleton, Wis.) implemented Carestream’s Vue for Clinical Collaboration Platform...